Equifax Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION

12 Months Ended

Dec. 31, 2022

Share-Based Payment Arrangement [Abstract]

We have one active share-based award plan, the amended and restated 2008 Omnibus Incentive Plan. This plan was originally approved by our shareholders in 2008 and was amended and restated with shareholder approval in May 2013 to, among other things, increase the reserve for awards under the plan by 11 million shares. The plan provides our directors, officers and certain key employees with stock options, restricted stock units and performance share awards. The plan is described below. We expect to issue common shares held as either treasury stock or new issue shares upon the exercise of stock options or once shares vest pursuant to restricted stock units or performance share awards. Total stock-based compensation expense in our Consolidated Statements of Income during the twelve months ended December 31, 2022, 2021 and 2020, was as follows:


	Twelve Months Ended December 31,
	2022		2021		2020
	(In millions)
Cost of services	$	12.4	$	12.0	$	11.2
Selling, general and administrative expenses	50.2		42.9		43.5
Stock-based compensation expense, before income taxes	$	62.6	$	54.9	$	54.7

The total income tax benefit recognized for stock-based compensation expense was $14.8 million, $13.0 million and $13.0 million for the twelve months ended December 31, 2022, 2021 and 2020, respectively.

Stock Options. The 2008 Omnibus Incentive Plan provides that qualified and nonqualified stock options may be granted to officers and other employees. The 2008 Omnibus Incentive Plan requires that stock options be granted at exercise prices not less than market value on the date of grant. Generally, stock options are subject to graded vesting for periods of up to three years based on service, with 33% vesting for each year of completed service, and expire ten years from the grant date.

We use the binomial model to calculate the fair value of stock options granted. The binomial model incorporates assumptions regarding anticipated employee exercise behavior, expected stock price volatility, dividend yield and risk-free interest rate. Anticipated employee exercise behavior and expected post-vesting cancellations over the contractual term used in the binomial model were primarily based on historical exercise patterns. These historical exercise patterns indicated there was not significantly different exercise behavior between employee groups. For our expected stock price volatility assumption, we weighted historical volatility and implied volatility. We used daily observations for historical volatility, while our implied volatility assumption was based on actively traded options related to our common stock. The expected term is derived from the binomial model based on assumptions incorporated into the binomial model as described above.

The fair value for stock options granted during the twelve months ended December 31, 2022, 2021 and 2020, was estimated at the date of grant, using the binomial model with the following weighted-average assumptions:


	Twelve Months Ended December 31,
	2022			2021			2020
Dividend yield	0.7		%	1.0		%	1.3		%
Expected volatility	31.5		%	28.5		%	23.5		%
Risk-free interest rate	2.4		%	0.5		%	1.3		%
Expected term (in years)	5.0			4.8			4.4
Weighted-average fair value of stock options granted	$	59.70		$	39.63		$	24.29

The following table summarizes changes in outstanding stock options during the twelve months ended December 31, 2022, as well as stock options that are vested and expected to vest and stock options exercisable at December 31, 2022:


	Shares	Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term	Aggregate Intrinsic Value
	(In thousands)			(In years)	(In millions)
Outstanding at December 31, 2021	1,710	$	149.67
Granted (all at market price)	369	$	232.28
Exercised	(76)	$	136.84
Forfeited and canceled	(39)	$	198.34
Outstanding at December 31, 2022	1,964	$	164.72	5.0	$	72.7
Vested and expected to vest at December 31, 2022	1,943	$	164.12	5.0	$	72.6
Exercisable at December 31, 2022	1,268	$	141.40	3.7	$	67.2

The aggregate intrinsic value amounts in the table above represent the difference between the closing price of Equifax’s common stock on December 31, 2022 and the exercise price, multiplied by the number of in-the-money stock options as of the same date. This represents the value that would have been received by the stock option holders if they had all exercised their stock options on December 31, 2022. In future periods, this amount will change depending on fluctuations in Equifax’s stock price. The total intrinsic value of stock options exercised during the twelve months ended December 31, 2022, 2021 and 2020, was $5.9 million, $41.9 million and $20.3 million, respectively. At December 31, 2022, our total unrecognized compensation cost related to stock options was $10.5 million with a weighted-average recognition period of 1.9 years.

The following table summarizes changes in outstanding options and the related weighted-average exercise price per share for the twelve months ended December 31, 2021 and 2020:


	December 31,
	2021			2020
	Shares	Weighted- Average Price		Shares	Weighted- Average Price
	(In thousands)			(In thousands)
Outstanding at the beginning of the year	1,831	$	137.01	1,825	$	122.46
Granted (all at market price)	314	$	184.03	433	$	158.62
Exercised	(341)	$	114.35	(365)	$	106.04
Forfeited and canceled	(94)	$	145.92	(62)	$	147.83
Outstanding at the end of the year	1,710	$	149.67	1,831	$	137.01
Exercisable at end of year	522	$	129.57	563	$	112.11

Other Stock Awards. Our 2008 Omnibus Incentive Plan also provides for awards of restricted stock units and performance shares or units that are settled in shares of our common stock that can be granted to executive officers, employees and directors. Such stock awards are generally subject to cliff vesting over a period between one to three years based on service and may also have vesting conditions based on meeting specified performance goals.

The fair value of these stock awards is based on the fair market value of our common stock on the date of grant. However, stock awards granted prior to February 16, 2017 did not accrue or pay dividends during the vesting period, so the fair value on the date of grant for the pre-2017 awards was reduced by the present value of the expected dividends over the requisite service period (discounted using the appropriate risk-free interest rate). Stock awards granted beginning in 2017 include the right to dividends or dividend equivalents, which are accrued and payable only if and when the underlying stock vests and is payable.

Pursuant to our 2008 Omnibus Incentive Plan, certain executives have been granted performance shares pursuant to which the number of shares earned is dependent upon the Company’s three-year total shareholder return relative to the three-year total shareholder return of the companies in the S&P 500 stock index, as comprised on the grant date, subject to adjustment. In 2017, certain executives were granted performance shares pursuant to which the number of shares earned was

dependent upon the Company’s three-year cumulative adjusted earnings per share. Beginning in 2022, certain executives have been granted performance shares pursuant to which the number of shares earned is dependent upon the Company's adjusted EBITDA growth over the three-year performance period.

The number of shares which could potentially be issued under these performance share awards ranges from zero to 200% of the target award. The grants outstanding subject to market performance as of December 31, 2022 would result in 291,376 shares outstanding at 100% of target and 582,752 at 200% of target at the end of the vesting period. Compensation expense for shares earned based on the Company’s three-year total shareholder return is recognized on a straight-line basis over the measurement period and is based upon the fair market value of the shares estimated to be earned at the date of grant using a Monte-Carlo simulation. Compensation expense for shares earned based on the Company’s three-year cumulative adjusted earnings per share was recognized on a straight-line basis over the measurement period based on the grant date fair value of our common stock and the number of awards expected to vest at each reporting date. Compensation expense for shares earned based on the Company’s adjusted EBITDA is recognized on a straight-line basis over the measurement period and is based upon the fair market value of the shares estimated to be earned at the date of grant using a Monte-Carlo simulation.

The following table summarizes changes in these other stock awards during the twelve months ended December 31, 2022, 2021 and 2020 and the related weighted-average grant date fair value:


	Shares	Weighted-Average Grant Date Fair Value
	(In thousands)
Nonvested at December 31, 2019	1,041	$	118.25
Granted	257	$	155.84
Vested	(279)	$	157.73
Forfeited	(92)	$	153.43
Nonvested at December 31, 2020	927	$	128.04
Granted	396	$	175.51
Vested	(465)	$	130.96
Forfeited	(79)	$	141.73
Nonvested at December 31, 2021	779	$	159.73
Granted	483	$	196.97
Vested	(406)	$	133.26
Forfeited	(72)	$	202.70
Nonvested at December 31, 2022	784	$	192.47

The total fair value of stock awards that vested during the twelve months ended December 31, 2022, 2021 and 2020, was $85.9 million, $106.7 million and $44.0 million, respectively, based on the weighted-average fair value on the vesting date, and $54.2 million, $61.0 million and $32.5 million, respectively, based on the weighted-average fair value on the date of grant. At December 31, 2022, our total unrecognized compensation cost related to these nonvested stock awards was $56.6 million with a weighted-average recognition period of 2.1 years.

Employee Stock Purchase Plan. Effective July 1, 2020, the Equifax board approved the 2020 Employee Stock Purchase Plan (“ESPP”). Under the ESPP, participating employees will have the option to withhold 1% - 10% of their annual salary, up to $25,000 annually, to purchase Equifax stock at a 5% discount based on the closing stock price of the final day of the offering period. The ESPP is noncompensatory in nature and is treated as any other sale of the Company's equity instruments.